Small intestinal mucosal injuries have been recently recognized as common complications associated with non-steroidal anti-inflammatory drugs (NSAIDs) because video capsule endoscopy and balloon enteroscopy are now available for the detection of small intestinal lesions. Small intestinal injury occurs not in an acid-dependent mechanism but by various factors such as enteric bacteria, bile acids, prostaglandin (PG) deficiency and topical factors (abnormal intestinal mucosal permeability, mitochondrial dysfunction, reactive oxygen species, endoplasmic reticulum stress and so on), and there is no well-established prophylactic approach. Several experimental and clinical studies found the effectiveness of some of the mucoprotective drugs, PG analogs, but not that of acid suppressants. Considering the effect of proton pump inhibitors (PPIs) for upper gastrointestinal (GI) disease and in the small intestine, the following 2 kinds of strategies against NSAID-induced GI injuries may be recommended. In patients with a high risk of upper GI disease (peptic ulcer etc.), simultaneous administration of a PPI (for upper GI disease) and a mucoprotective drug (for small intestine) is needed to prevent NSAID-induced GI injury. In other cases, an effective mucoprotective drug is enough for the protection of the entire digestive tract, that is, starting from the esophagus to the small intestine. These strategies may fulfill both economical and curative effects.

1.
Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI: Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992;327:749-754.
[PubMed]
2.
Konturek SJ, Brzozowski T, Piastucki I, Radecki T: Gastric cytoprotection by acetazolamide: role of endogenous prostaglandins. Digestion 1983;28:125-131.
[PubMed]
3.
Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG; Investigators: Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133-141.
[PubMed]
4.
Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I: A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005;128:1172-1178.
[PubMed]
5.
Sugimori S, Watanabe T, Tabuchi M, Kameda N, Machida H, Okazaki H, Tanigawa T, Yamagami H, Shiba M, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Koike T, Higuchi K, Arakawa T: Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: effects of anti-rheumatoid arthritis drugs. Digestion 2008;78:208-213.
[PubMed]
6.
Neumann H, Fry LC, Neurath MF: Review article on current applications and future concepts of capsule endoscopy. Digestion 2013;87:91-99.
[PubMed]
7.
Marlicz W, Loniewski I, Grimes DS, Quigley EM: Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine. Mayo Clin Proc 2014;89:1699-1709.
[PubMed]
8.
Robert A, Asano T: Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 1977;14:333-341.
[PubMed]
9.
Weissenborn U, Maedge S, Buettner D, Sewing KF: Indometacin-induced gastrointestinal lesions in relation to tissue concentration, food intake and bacterial invasion in the rat. Pharmacology 1985;30:32-39.
[PubMed]
10.
Zhou Y, Dial EJ, Doyen R, Lichtenberger LM: Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal anti-inflammatory drugs. Am J Physiol Gastrointest Liver Physiol 2010;298:G722-G731.
[PubMed]
11.
Wallace JL: NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol 2012;165:67-74.
[PubMed]
12.
Takeuchi K, Satoh H: NSAID-induced small intestinal damage - roles of various pathogenic factors. Digestion 2015;91:218-232.
[PubMed]
13.
Higuchi K, Umegaki E, Watanabe T, Yoda Y, Morita E, Murano M, Tokioka S, Arakawa T: Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 2009;44:879-888.
[PubMed]
14.
Reuter B, Davies NM, Wallace JL: Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997;112:109-117.
[PubMed]
15.
Bjarnason I, Hayllar J, MacPherson AJ, Russell AS: Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832-1847.
[PubMed]
16.
Basivireddy J, Vasudevan A, Jacob M, Balasubramanian KA: Indomethacin-induced mitochondrial dysfunction and oxidative stress in villus enterocytes. Biochem Pharmacol 2002;64:339-349.
[PubMed]
17.
Basivireddy J, Jacob M, Ramamoorthy P, Pulimood AB, Balasubramanian KA: Indomethacin-induced free radical-mediated changes in the intestinal brush border membranes. Biochem Pharmacol 2003;65:683-695.
[PubMed]
18.
Handa O, Majima A, Onozawa Y, Horie H, Uehara Y, Fukui A, Omatsu T, Naito Y, Yoshikawa T: The role of mitochondria-derived reactive oxygen species in the pathogenesis of non-steroidal anti-inflammatory drug-induced small intestinal injury. Free Radic Res 2014;48:1095-1099.
[PubMed]
19.
Tanaka K, Tomisato W, Hoshino T, Ishihara T, Namba T, Aburaya M, Katsu T, Suzuki K, Tsutsumi S, Mizushima T: Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis. J Biol Chem 2005;280:31059-31067.
[PubMed]
20.
Tsutsumi S, Gotoh T, Tomisato W, Mima S, Hoshino T, Hwang HJ, Takenaka H, Tsuchiya T, Mori M, Mizushima T: Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ 2004;11:1009-1016.
[PubMed]
21.
Narabayashi K, Ito Y, Eid N, Maemura K, Inoue T, Takeuchi T, Otsuki Y, Higuchi K: Indomethacin suppresses LAMP-2 expression and induces lipophagy and lipoapoptosis in rat enterocytes via the ER stress pathway. J Gastroenterol 2015;50:541-544.
[PubMed]
22.
Edogawa S, Sakai A, Inoue T, Harada S, Takeuchi T, Umegaki E, Hayashi H, Higuchi K: Down-regulation of collagen I biosynthesis in intestinal epithelial cells exposed to indomethacin: a comparative proteome analysis. J Proteomics 2014;103:35-46.
[PubMed]
23.
Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, Nomoto K, Takeuchi K, Arakawa T: Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 2008;57:181-187.
[PubMed]
24.
Boelsterli UA, Redinbo MR, Saitta KS: Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies. Toxicol Sci 2013;131:654-667.
[PubMed]
25.
Hawkey CJ, Karrasch JA, Szczepañski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus misoprostol for NSAID-induced ulcer management (OMNIUM) study group. N Engl J Med 1998;338:727-734.
[PubMed]
26.
Yoda Y, Takeuchi K, Kato S, Amagase K, Umegaki E, Tokioka S, Higuchi K: Search for prophylactic drugs against NSAID-induced small intestinal lesions in rats. Gastroenterology 2008;134(suppl 1):A-528.
27.
Park SH, Cho CS, Lee OY, Jun JB, Lin SR, Zhou LY, Yuan YZ, Li ZS, Hou XH, Zhao HC, Kachintorn U, Kositchaiwat C, Lertkupinit C: Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM study. J Clin Biochem Nutr 2007;40:148-155.
[PubMed]
28.
Suemasu S, Tanaka K, Namba T, Ishihara T, Katsu T, Fujimoto M, Adachi H, Sobue G, Takeuchi K, Nakai A, Mizushima T: A role for HSP70 in protecting against indomethacin-induced gastric lesions. J Biol Chem 2009;284:19705-19715.
[PubMed]
29.
Zhang X, Tajima K, Kageyama K, Kyoi T: Irsogladine maleate suppresses indomethacin-induced elevation of proinflammatory cytokines and gastric injury in rats. World J Gastroenterol 2008;14:4784-4790.
[PubMed]
30.
Koizumi W, Tanabe S, Imaizumi H, Kida M, Ohida M, Koshida Y, Mitomi H, Hosaka Y, Nagaba S, Sasaki T, Higuchi K, Saigenji K: Inhibition of peptic ulcer relapse by ranitidine and ecabet independently of eradication of helicobacter pylori: a prospective, controlled study versus ranitidine. Hepatogastroenterology 2003;50:577-581.
[PubMed]
31.
Higuchi K, Watanabe T, Tominaga K, Shiba M, Nakagawa K, Uno H, Kitada K, Satoh H, Chono S, Oshitani N, Fujiwara Y, Arakawa T: Lafutidine can improve the quality of gastric ulcer healing in humans: a randomized, controlled, multicenter trial. Inflammopharmacology 2006;14:226-230.
[PubMed]
32.
Müller P, Jackisch P, Simon B: [Comparison of the protective effects of roxatidine and misoprostol on diclofenac gastroduodenal pathology. An endoscopic, controlled study of volunteers]. Arzneimittelforschung 1994;44:1127-1129.
[PubMed]
33.
Yoda Y, Amagase K, Kato S, Tokioka S, Murano M, Kakimoto K, Nishio H, Umegaki E, Takeuchi K, Higuchi K: Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of heme oxygenase-1. J Physiol Pharmacol 2010;61:287-294.
[PubMed]
34.
Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E: Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011;141:1314-1322.
[PubMed]
35.
Hayashi S, Kurata N, Yamaguchi A, Amagase K, Takeuchi K: Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors. J Pharmacol Exp Ther 2014;349:470-479.
[PubMed]
36.
Rácz I, Szalai M, Kovács V, Regőczi H, Kiss G, Horváth Z: Mucosal healing effect of mesalazine granules in naproxen-induced small bowel enteropathy. World J Gastroenterol 2013;19:889-896.
[PubMed]
37.
Inoue T, Higashiyama M, Kaji I, Rudenkyy S, Higuchi K, Guth PH, Engel E, Kaunitz JD, Akiba Y: Dipeptidyl peptidase IV inhibition prevents the formation and promotes the healing of indomethacin-induced intestinal ulcers in rats. Dig Dis Sci 2014;59:1286-1295.
[PubMed]
38.
Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, Hirooka Y, Goto H: Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol 2008;43:270-276.
[PubMed]
39.
Fujimori S, Takahashi Y, Gudis K, Seo T, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C: Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol 2011;46:57-64.
[PubMed]
40.
Mizukami K, Murakami K, Abe T, Inoue K, Uchida M, Okimoto T, Kodama M, Fujioka T: Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol 2011;17:5117-5122.
[PubMed]
41.
Kurokawa S, Katsuki S, Fujita T, Saitoh Y, Ohta H, Nishikawa K, Sato Y, Sato Y, Ohira K, Yamada M, Kato M: A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol 2014;49:239-244.
[PubMed]
42.
Niwa Y, Nakamura M, Miyahara R, Ohmiya N, Watanabe O, Ando T, Kawashima H, Itoh A, Hirooka Y, Goto H: Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects: a prospective randomized placebo-controlled double-blind cross-over study. Digestion 2009;80:260-266.
[PubMed]
43.
Umegaki E, Kuramoto T, Kojima Y, Nouda S, Ishida K, Takeuchi T, Inoue T, Tokioka S, Higuchi K: Geranylgeranylacetone, a gastromucoprotective drug, protects against NSAID-induced esophageal, gastroduodenal and small intestinal mucosal injury in healthy subjects: a prospective randomized study involving a comparison with famotidine. Intern Med 2014;53:283-290.
[PubMed]
44.
Isomura Y, Yamaji Y, Yamada A, Watanabe Y, Suzuki H, Kobayashi Y, Yoshida S, Watabe H, Hirata Y, Yoshida H, Koike K: Irsogladine improves small-intestinal injuries in regular users of nonsteroidal anti-inflammatory drugs. Gastrointest Endosc 2014;80:118-125.
[PubMed]
45.
Kuramoto T, Umegaki E, Nouda S, Narabayashi K, Kojima Y, Yoda Y, Ishida K, Kawakami K, Abe Y, Takeuchi T, Inoue T, Murano M, Tokioka S, Higuchi K: Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. BMC Gastroenterol 2013;13:85.
[PubMed]
46.
Fujimori S, Seo T, Gudis K, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C: Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc 2009;69:1339-1346.
[PubMed]
47.
Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ: Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989;34:407-411.
[PubMed]
48.
Watanabe T, Sugimori S, Kameda N, Machida H, Okazaki H, Tanigawa T, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Higuchi K, Arakawa T: Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008;6:1279-1282.
[PubMed]
49.
Davies GR, Wilkie ME, Rampton DS: Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig Dis Sci 1993;38:417-425.
[PubMed]
50.
Bjarnason I, Hayllar J, Smethurst P, Price A, Gumpel MJ: Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 1992;33:1204-1208.
[PubMed]
51.
Montalto M, Gallo A, Gasbarrini A, Landolfi R: NSAID enteropathy: could probiotics prevent it? J Gastroenterol 2013;48:689-697.
[PubMed]
52.
Endo H, Higurashi T, Hosono K, Sakai E, Sekino Y, Iida H, Sakamoto Y, Koide T, Takahashi H, Yoneda M, Tokoro C, Inamori M, Abe Y, Nakajima A: Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol 2011;46:894-905.
[PubMed]
53.
Montalto M, Gallo A, Curigliano V, D'Onofrio F, Santoro L, Covino M, Dalvai S, Gasbarrini A, Gasbarrini G: Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy - a randomized, double-blind, cross-over, placebo-controlled study. Aliment Pharmacol Ther 2010;32:209-214.
[PubMed]
54.
Watanabe T, Tanigawa T, Nadatani Y, Nagami Y, Sugimori S, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Koike T, Arakawa T: Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage. Dig Liver Dis 2013;45:390-395.
[PubMed]
55.
Sakai E, Endo H, Taniguchi L, Hata Y, Ezuka A, Nagase H, Yamada E, Ohkubo H, Higurashi T, Sekino Y, Koide T, Iida H, Hosono K, Nonaka T, Takahashi H, Inamori M, Maeda S, Nakajima A: Factors predicting the presence of small bowel lesions in patients with obscure gastrointestinal bleeding. Dig Endosc 2013;25:412-420.
[PubMed]
56.
Kojima Y, Kuramoto T, Nouda S, Narabayashi K, Ishida K, Kawakami K, Abe Y, Takeuchi T, Inoue T, Tokioka S, Umegaki E, Higuchi K: Sa1624 Effect of long-term PPI administration on NSAID-induced small intestinal lesions and therapeutic effect of irsogladine, a gastroprotective drug, for such lesions in healthy volunteers. Gastrointest Endosc 2013;77:AB271-AB272.
You do not currently have access to this content.